Fairtree Asset Management Pty Ltd Buys Shares of 7,556 Stryker Corporation $SYK

Fairtree Asset Management Pty Ltd acquired a new stake in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,556 shares of the medical technology company’s stock, valued at approximately $2,379,000. Stryker accounts for about 0.9% of Fairtree Asset Management Pty Ltd’s holdings, making the stock its 27th largest holding.

Other hedge funds have also made changes to their positions in the company. Sankala Group LLC purchased a new position in Stryker during the fourth quarter worth about $26,000. Godfrey Financial Associates Inc. purchased a new stake in Stryker in the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker during the 4th quarter worth about $27,000. Finally, Gables Capital Management Inc. purchased a new position in shares of Stryker during the 2nd quarter worth about $25,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent analyst reports. Raymond James Financial set a $370.00 target price on shares of Stryker in a report on Friday, July 31st. Evercore set a $350.00 price target on shares of Stryker in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research note on Friday, May 1st. Barclays dropped their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Finally, Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Price Performance

SYK opened at $327.97 on Friday. The company has a fifty day simple moving average of $326.64 and a 200 day simple moving average of $332.66. The firm has a market cap of $125.80 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 665,370 shares of company stock worth $216,238,501. 4.60% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.